vs
Side-by-side financial comparison of TPG Mortgage Investment Trust, Inc. (MITT) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
TPG Mortgage Investment Trust, Inc. is the larger business by last-quarter revenue ($20.4M vs $18.6M, roughly 1.1× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 65.0%, a 0.8% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 17.7%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 9.1%).
TPG Mortgage Investment Trust, Inc. is a real estate investment trust managed by global alternative asset firm TPG. It primarily invests in residential and commercial mortgage-backed securities, performing and non-performing mortgage loans, and other credit-linked real estate assets, with its core market being the United States. It generates returns via net interest income from holdings and strategic asset disposition gains.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
MITT vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.4M | $18.6M |
| Net Profit | $13.3M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 67.1% | 56.3% |
| Net Margin | 65.0% | 65.7% |
| Revenue YoY | 17.7% | 1808.5% |
| Net Profit YoY | -7.0% | 376.5% |
| EPS (diluted) | $0.27 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.4M | $18.6M | ||
| Q3 25 | $19.5M | $334.0K | ||
| Q2 25 | $17.8M | $1.4M | ||
| Q1 25 | $18.8M | $257.0K | ||
| Q4 24 | $17.4M | $977.0K | ||
| Q3 24 | $14.9M | $660.0K | ||
| Q2 24 | $16.4M | $736.0K | ||
| Q1 24 | $17.2M | $1.4M |
| Q4 25 | $13.3M | $12.3M | ||
| Q3 25 | $20.0M | $-8.6M | ||
| Q2 25 | $3.9M | $-6.9M | ||
| Q1 25 | $11.5M | $-5.4M | ||
| Q4 24 | $14.3M | — | ||
| Q3 24 | $16.6M | $-2.8M | ||
| Q2 24 | $3.9M | $-14.5M | ||
| Q1 24 | $20.9M | $411.0K |
| Q4 25 | 67.1% | 56.3% | ||
| Q3 25 | — | -2516.5% | ||
| Q2 25 | 20.9% | -701.0% | ||
| Q1 25 | 54.6% | -3350.2% | ||
| Q4 24 | 76.7% | — | ||
| Q3 24 | — | -1563.6% | ||
| Q2 24 | 18.4% | -1255.0% | ||
| Q1 24 | — | -692.5% |
| Q4 25 | 65.0% | 65.7% | ||
| Q3 25 | 102.5% | -2572.2% | ||
| Q2 25 | 22.2% | -504.8% | ||
| Q1 25 | 60.9% | -2097.7% | ||
| Q4 24 | 82.2% | — | ||
| Q3 24 | 111.3% | -425.5% | ||
| Q2 24 | 24.0% | -1964.4% | ||
| Q1 24 | 121.6% | 29.9% |
| Q4 25 | $0.27 | $0.25 | ||
| Q3 25 | $0.47 | $-0.17 | ||
| Q2 25 | $-0.05 | $-0.14 | ||
| Q1 25 | $0.21 | $-0.11 | ||
| Q4 24 | $0.30 | — | ||
| Q3 24 | $0.40 | $-0.06 | ||
| Q2 24 | $-0.02 | $-0.30 | ||
| Q1 24 | $0.55 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $57.8M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $560.7M | $49.4M |
| Total Assets | $8.7B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $57.8M | $40.0M | ||
| Q3 25 | $59.0M | $37.9M | ||
| Q2 25 | $88.7M | $44.8M | ||
| Q1 25 | $115.5M | $40.6M | ||
| Q4 24 | $118.7M | $59.3M | ||
| Q3 24 | $102.5M | $68.8M | ||
| Q2 24 | $120.9M | $73.0M | ||
| Q1 24 | $100.3M | $80.2M |
| Q4 25 | $560.7M | $49.4M | ||
| Q3 25 | $559.8M | $36.4M | ||
| Q2 25 | $536.4M | $44.5M | ||
| Q1 25 | $543.9M | $50.5M | ||
| Q4 24 | $543.4M | $55.1M | ||
| Q3 24 | $540.1M | $58.5M | ||
| Q2 24 | $533.5M | $60.4M | ||
| Q1 24 | $539.6M | $74.1M |
| Q4 25 | $8.7B | $59.0M | ||
| Q3 25 | $9.0B | $51.1M | ||
| Q2 25 | $7.5B | $60.7M | ||
| Q1 25 | $7.3B | $67.9M | ||
| Q4 24 | $6.9B | $90.6M | ||
| Q3 24 | $7.0B | $99.0M | ||
| Q2 24 | $7.1B | $107.8M | ||
| Q1 24 | $6.4B | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $59.6M | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 4.48× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $59.6M | $18.4M | ||
| Q3 25 | $17.4M | $-8.7M | ||
| Q2 25 | $11.5M | $-7.5M | ||
| Q1 25 | $12.0M | $-7.5M | ||
| Q4 24 | $55.8M | $-24.0M | ||
| Q3 24 | $14.5M | $765.0K | ||
| Q2 24 | $13.7M | $-10.9M | ||
| Q1 24 | $12.0M | $-4.0M |
| Q4 25 | 4.48× | 1.50× | ||
| Q3 25 | 0.87× | — | ||
| Q2 25 | 2.92× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 3.91× | — | ||
| Q3 24 | 0.87× | — | ||
| Q2 24 | 3.50× | — | ||
| Q1 24 | 0.57× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MITT
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
